Phase 2 N=49 Vaginal Diazepam for the Treatment of Female Pelvic Pain
Pelvic Floor Disorders · Pelvic Pain
Primary: Visual Analog Scale (VAS) for Pain — 50; 39 score on a scale — p=0.62
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Colorectal Cancer · Metastatic Colorectal Cancer · RAS Wild Type Colorectal Cancer
Primary: Maximum Tolerated Dose (Phase I) of CB-839 in Combination With Panitumumab and Irinotecan Hydrochloride — 800 mg
Phase 2 N=49 Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma · Untreated
Primary: 3-year Progression-free Survival (PFS) — 63 % of pts progression-free survival
Phase 2 N=397 Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Osteoarthritis of Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A Pain Score — -1.28; -1.35; -1.14; -0.96 score on a scale — p=0.850
Phase 2 N=46 Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic
Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
Phase 2 N=714 A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
Kidney Disease, Chronic
Primary: Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients…
Phase 2 N=31 Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Stage III Fallopian Tube Cancer AJCC v7 · Stage III Ovarian Cancer AJCC v6 and v7 · Stage III Primary Peritoneal Cancer AJCC v7
Primary: To Evaluate Progression-free Survival of Paclitaxel/Carboplatin and Pembrolizumab in Patients With Advanced Stage, Metastatic Ovarian Cancer Undergoing NACT — 14.2 months
Phase 2 N=80 Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos
Cigarette Smoking
Primary: Percentage of Participants Achieving Biochemically Verified 7-day Point Prevalence Abstinence at 3 Months — 10; 24; 29; 16 Participants
Phase 2 N=58 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
Thrombotic Microangiopathies
Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA — 0; 0; 27 Participants
Phase 2 N=80 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Metastatic Pancreatic Adenocarcinoma
Primary: Objective Response Rate (ORR) Assessed by Imaging According to RECIST 1.1 Criteria — 1; 8 Participants
Phase 2 N=41 Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) — 34.5 percentage of participants
Phase 2 N=313 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
Leprosy
Primary: Mean Difference in QTc Interval Between the Two Arms 24 Hours After Treatment Administration — 396.81; 397; 404.61; 394.06 msec
Phase 2 N=28 Effects of Tolcapone on Frontotemporal Dementia
Frontotemporal Lobar Degeneration
Primary: Reaction Time on the N-back Cognitive Test (0-back Condition) — 7935; 8322 milliseconds
Phase 2 N=52 AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
Relapsed/Refractory Peripheral T-cell Lymphoma · Relapsed/Refractory Classical Hodgkins Lymphoma
Primary: Objective Response Rate (ORR) — 22.6; 0; 21.1 Percentage of participants